Cargando…

Peripheral T-Cell Lymphoma with Aberrant Expression of CD19, CD20, and CD79a: Case Report and Literature Review

A case of lymphoma of T-cell derivation with aberrant expression of three B-cell lineage markers (CD19, CD20, and CD79a), which was diagnosed on a left axillary excision, is described. Immunohistochemical studies and flow cytometry analysis demonstrated neoplastic cells expressing CD3, CD19, CD20, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matnani, Rahul G., Stewart, Rachel L., Pulliam, Joseph, Jennings, Chester D., Kesler, Melissa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771455/ https://www.ncbi.nlm.nih.gov/pubmed/24066244 http://dx.doi.org/10.1155/2013/183134

Ejemplares similares

Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature
por: Mangogna, Alessandro, et al.
Publicado: (2020)

Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia
por: Jovanovic, Danijela, et al.
Publicado: (2014)

CD20/CD79a/PAX5/CD3-negative post-transplant lymphoma with aberrant actin and desmin co-expression—a potential differential diagnostic pitfall between PTLD and PTSMT
por: Suhren, Jan-Theile, et al.
Publicado: (2022)

United we stand: Double targeting of CD79B and CD20 in diffuse large B‐cell lymphoma
por: Tarantelli, Chiara, et al.
Publicado: (2022)

Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma
por: Sakatani, Akio, et al.
Publicado: (2020)

CD3+, CD56+, CD4−, CD8−, CD20−, CD30− Peripheral T-Cell Non-Hodgkin's Lymphoma: A Rare Case Report
por: Jagati, Ashish, et al.
Publicado: (2017)

Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells
por: He, Xiaocui, et al.
Publicado: (2018)

CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma
por: Trøen, Gunhild, et al.
Publicado: (2013)

Aberrant CD3-Positive, CD8-Low, CD7-Negative Lymphocytes May Appear During Viral Infections and Mimic Peripheral T-Cell Lymphoma
por: Klameth, Andreas, et al.
Publicado: (2020)

Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
por: Chu, Fuliang, et al.
Publicado: (2023)

P1237: PRELIMINARY RESULTS OF A PHASE Ⅱ STUDY OF ZANUBRUTINIB COMBINED WITH IMMUNOCHEMOTHERAPY IN PATIENTS WITH CD79A/CD79B-MUTANT DIFFUSE LARGE B-CELL LYMPHOMA
por: Yan, Z., et al.
Publicado: (2022)

Small round tumour cells (CD38, CD 79a positive) in the adrenal gland
por: Nigam, L.A., et al.
Publicado: (2017)

Preliminary In Vitro Effects of CD8+ T Lymphocyte Specific for the CD20 Alternative Splicing D393-CD20 Peptide Expressed on Burkitt Lymphoma Cells
por: Chegni, Hamid, et al.
Publicado: (2019)

Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20(+)CD27(+)CD43(+)CD70(−)
por: Griffin, Daniel O., et al.
Publicado: (2011)

Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20(+)CD27(+)CD43(+)CD70(−)
por: Griffin, Daniel O., et al.
Publicado: (2011)

Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20(+)CD27(+)CD43(+)CD70(−)
por: Griffin, Daniel O., et al.
Publicado: (2011)

The predictive significance of CD20 expression in B-cell lymphomas
por: Prevodnik, Veronika Kloboves, et al.
Publicado: (2011)

Canine Mammary Neoplasia Induces Variations in the Peripheral Blood Levels of CD20, CD45RA, and CD99
por: Galadima, Makchit, et al.
Publicado: (2023)

Multiples aberrant phenotypes in multiple myeloma patient expressing CD56(-), CD28(+),CD19(+)
por: Leite, Luiz Arthur Calheiros, et al.
Publicado: (2012)

CD20 Positive T Cell Lymphoma Involvement of Skin
por: Lee, Ki Yeol, et al.
Publicado: (2011)

Novel CD20 monoclonal antibodies for lymphoma therapy
por: Cang, Shundong, et al.
Publicado: (2012)

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity
por: Shinoda, Koji, et al.
Publicado: (2023)

Human CD79b(+) neutrophils in the blood are associated with early-stage melanoma
por: Meyer, Melissa A., et al.
Publicado: (2023)

Relapsed angioimmunoblastic T-cell lymphoma with acquired expression of CD20: a case report and review of the literature
por: Banz, Yara, et al.
Publicado: (2013)

5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report
por: Tsutsumi, Yutaka, et al.
Publicado: (2016)

Diagnosis and treatment of CD20 negative B cell lymphomas
por: Katchi, Tasleem, et al.
Publicado: (2017)

Enrichment of T-cell proliferation and memory gene signatures of CD79A/CD40 costimulatory domain potentiates CD19CAR-T cell functions
por: Ung, Socheatraksmey, et al.
Publicado: (2022)

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group
por: Wada, Naoki, et al.
Publicado: (2009)

Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature
por: Juárez-Salcedo, Luis Miguel, et al.
Publicado: (2020)

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
por: Gui, Lin, et al.
Publicado: (2016)

Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells
por: Fuh, Franklin K, et al.
Publicado: (2017)

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
por: Leung, Isabel, et al.
Publicado: (2022)

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
por: Liu, Yanlong, et al.
Publicado: (2022)

Aberrant Loss of Surface CD3 and TCRγδ Expression in Relapsed Hepatosplenic T-cell Lymphoma
por: Lee, Beomki, et al.
Publicado: (2021)

Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma
por: Nagel, Daniel, et al.
Publicado: (2015)

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations
por: Kersten, M J, et al.
Publicado: (2014)

Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice
por: Visco, Carlo, et al.
Publicado: (2020)

Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas
por: Yi, Jun Ho
Publicado: (2021)

Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells
por: Polito, Letizia, et al.
Publicado: (2017)

CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
por: Liu, Xinyuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c77m1mb9ld9ipc44dbo6ranfpa